Média

Onxeo announces positive intermediate results from the first part of the DRIIV-1b study evaluating AsiDNA™ in combination with chemotherapy

Stabilized disease without tumor progression for two of the three treated patients who are still receiving treatment with AsiDNA™ plus carboplatin Satisfactory tolerance allowing the continuation of the study Start of the second part of the study to evaluate AsiDNA™ in combination with carboplatin and paclitaxel, a reference treatment protocol for many cancers Preliminary results from this second part are…read more →

Onxeo to Attend Key Investor and Scientific Conferences

Paris (France), September 11, 2019 – 5.45 pm CEST – Onxeo S.A. (Euronext Paris, NASDAQ Copenhagen: ONXEO – FR0010095596), (“Onxeo” or “the Company”), a clinical-stage biotechnology company specializing in the development of innovative drugs targeting tumor DNA Damage response (DDR) in oncology, in particular against rare or resistant cancers, today announced that its management team will attend the following key…read more →

Publication of the 2019 Half-Yearly Financial Report

Paris (France), July 31, 2019 – 7.00 pm CEST – Onxeo S.A. (Euronext Paris, NASDAQ Copenhagen: ONXEO – FR0010095596), (“Onxeo” or “the Company”), a clinical-stage biotechnology company specializing in the development of innovative drugs targeting tumor DNA Damage response (DDR) in oncology, in particular against rare or resistant cancers, today announced the publication of the Company’s 2019 half-yearly financial report….read more →

Onxeo Reports Half-Year 2019 Financial Results and Provides Business Update

Finalization of DRIIV-1 Phase 1 study confirming AsiDNA™ activity and safety profile Initiation of DRIIV-1b study of AsiDNA™ with chemotherapy, on track with preliminary results expected end H2 2019 and final results in H1 2020 New optimized lead OX401 undergoing proof-of-concept preclinical studies Cash position of €6.3 million at June 30, 2019 complemented by the Nice & Green equity line,…read more →

AsiDNA™ Letter – No. 2

AsiDNA™ Letter – No. 2 Role of AsiDNA™ in the new combination strategies Ladies, Gentlemen and shareholders The complexity and diversity of cancers require multiple therapeutic approaches. The combination of several anti-cancer agents has become the norm in oncology, especially to treat the very aggressive or resistant cancers. Thanks to its original anti-tumor activity and its good tolerance already clinically demonstrated, AsiDNA™ is…read more →

AsiDNA™ Letter – No. 1

Ladies, Gentlemen and Shareholders, The clinical development of AsiDNA™ is well on its way and we would like to inform you regularly about the progress being made through a Letter dedicated to this first-in-class candidate. In this first issue, we go back to the fundamentals of the DNA Damage Response (DDR) therapeutic approach in oncology, which consists of fighting cancer…read more →

The equity research company KEPLER CHEUVREUX initiates the coverage of ONXEO with a “Buy” recommendation

Paris (France), July 1st, 2019 – 7:00 a.m. CEST – Onxeo S.A. (Euronext Paris, NASDAQ Copenhagen: ONXEO), (hereinafter “Onxeo” or “the Company”), a clinical-stage biotechnology company specializing in the development of innovative drugs targeting tumor DNA Damage Response (DDR) in oncology, in particular against rare or resistant cancers, today announced the publication of an initiation report by KEPLER CHEUVREUX, a…read more →

Onxeo Expands its Pipeline with New Optimized Lead OX401 Entering Proof-of-Concept Preclinical Phase

OX401 is the second candidate utilizing Onxeo’s proprietary platform of decoy agonists, platON™ OX401 is optimized to be a next-generation PARP inhibitor, designed to act on both the DNA Damage Response and the activation of immune response In vivo proof-of-concept results alone and in combination with cancer immunotherapies are expected by early Q4 2019   Paris (France), June 20, 2019…read more →

Onxeo renews its equity financing line with Nice & Green as part of the financing of its business and strategic activities

     The new financing line could represent a total of approximately €9 million over the upcoming 12 months, based on current stock price levels, extending the cash runway until Q3 2020      It may be suspended or terminated by Onxeo at any time      It provides Onxeo with the means to finance key activities over the next 12 months and…read more →

Onxeo announces final positive data from DRIIV-1 Phase 1 Study of AsiDNA™ in Advanced Solid Tumors

Primary safety and activity endpoints met Favorable safety profile, maximum tolerated dose not reached, optimal active dose determined AsiDNA™ induced the intratumoral activation of its DNA-PK target, confirming its mechanism of action The full results of the study will be presented at upcoming international scientific meetings Paris (France), May 28, 2019 – 6:00 pm CEST – Onxeo S.A. (Euronext Paris,…read more →

Ordinary General Meeting of May 22, 2019

Renewal of the terms of office of Danièle Guyot-Caparros, Jean-Pierre Bizzari and Jean-Pierre Kinet Appointment of Danièle Guyot-Caparros as Chairman of the Board of Directors Paris (France), May 22, 2019 – 6:00 pm CEST – Onxeo S.A. (Euronext Paris, NASDAQ Copenhagen: ONXEO), (“Onxeo” or “the Company”), a clinical-stage biotechnology company specializing in the development of innovative drugs targeting tumor DNA…read more →

Abstract – Journal of Clinical Oncology

Moving From Poly (ADP-Ribose) Polymerase Inhibition to Targeting DNA Repair and DNA Damage Response in Cancer Therapy A reference paper on new approaches in the field of DDR, including AsiDNA™, and their interest in combination treatments Link to the article: https://ascopubs.org/doi/10.1200/JCO.18.02050

Onxeo Announces Treatment of First Patient in DRIIV-1b, a Phase 1b Clinical Trial of AsiDNA™ in Combination with Chemotherapy

DRIIV-1b is designed to assess the clinical potential of AsiDNA™ in combination with carboplatin and with carboplatin plus paclitaxel in patients with solid tumors eligible to such treatments Initial results are expected in the second half of 2019   Paris (France), Mai 6, 2019 – 6:00 pm CEST – Onxeo S.A. (Euronext Paris, NASDAQ Copenhagen: ONXEO), (“Onxeo” or “the Company”),…read more →

Publication of the 2018 Registration Document

Paris (France), April 8, 2019 – 5:45 pm CEST – Onxeo S.A. (Euronext Paris, NASDAQ Copenhagen: ONXEO), a biotechnology company specializing in the development of innovative drugs for the treatment of orphan diseases, in particular in oncology, today announced the publication of the Company’s 2018 Registration Document. The 2018 Registration Document, filed with the French Market Authorities (Autorité des Marchés…read more →